Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (556)	12/18/1997 7:53:00 PM
From: Double Dipper	Respond to of 887

I find it hard to believe that this study was so marginal and yet the statistics were not picked up on by anyone. The panel however didn't miss them. I don't know where the stock will end up tommorow but I hope their research continues and someday they may prevail. For me I'll be licking my modest wounds elsewhere trying to recover back in the oil or tech sectors. You know, someplace where its safe (bad joke). Kevin

To: seminole who wrote (556)	12/18/1997 7:55:00 PM
From: John McCarthy	Read Replies (2) \| Respond to of 887

To this thread: What follows are the exact words in an IBD article from the summer of 1996. ===================================================== DepoCyt completed Phase III clinical trials, ..... Trial results released last week show that DepoCyt worked TWICE as well as the standard drug therapy, called methotrexate. DepoCyt wiped out cancer cells in 36% of patients taking it,while methotrexate killed the cancer in on 17% of patients, DepoTech said. The results involved 54 patients with solid tumors. Moreover, an interim analysis showed that, out of 32 patients tested, the mean survival rate of those who took DepoCyt was 277 days, compared to 68 days for patients in the control group. Final survival rates will be released over the next few months. ===================================================== The above statements are in great contrast to what I am hearing from the FDA meeting today. Can somebody reconcile the discrepency? Regards, John McCarthy